Your browser is out-of-date!

Update your browser to view this website correctly. Update my browser now

×

Discipline
Biological
Keywords
Prodigiosin
Bacillus Oleronius
Rosacea
Antimicrobial
Natural Product
Observation Type
Follow-up
Nature
Continuing the storyline
Submitted
Mar 14th, 2019
Published
Jan 30th, 2020
  • Abstract

    Prodigiosin is a red bacterial pigment that exhibits antimicrobial activity against a wide range of microorganisms. Bacillus oleronius is a bacterium that is associated with rosacea, a long-term skin condition that affects the face and typically results in pimples, redness, and swelling of the skin. We explored the effect of prodigiosin on the growth of B. oleronius. Prodigiosin completely inhibited the growth of B. oleronius in a broth microdilution assay at 0.75 (0.289) μg/mL, lower than previously reported minimum inhibitory concentration values for other species of Bacillus. We also observed a rapid decline in the optical density of mid-log phase B. oleronius cultures immediately upon treatment with prodigiosin, suggesting that prodigiosin exerts bactericidal activity on actively dividing cells.

  • Figure
  • Introduction

    Rosacea is a facial skin disorder that causes a wide range of symptoms from persistent redness of the skin to eye irritation. It is a chronic inflammatory disease with a typical onset at age 30 or older. Rosacea is estimated to affect 5.46% of the global adult population. In the United States, an estimated 82% of rosacea cases remain untreated, resulting in long-term skin conditions that are sometimes characterized by cycles of remission and relapse.

    While the exact cause of rosacea is unknown, a growing body of literature suggests that the condition may be caused or exacerbated by the presence of a bacterium called Bacillus oleronius. Compared to the general population, rosacea patients are more likely to have circulating antibodies against B. oleronius, suggesting previous exposure to and immune response against the bacterium. Additionally, B. oleronius proteins have the ability to activate peripheral blood mononuclear cells and neutrophils, causing the release of pro-inflammatory cytokines. More generally, some antibiotics of the tetracycline and macrolide groups are effective in the treatment of some types of rosacea, suggesting that a bacterial agent may be involved in the pathogenesis of the disease. However, these antibiotics also have an anti-inflammatory response that likely alleviates rosacea symptoms. The potential association between B. oleronius and rosacea is further complicated by the bacterium’s commensal relationship with Demodex folliculorum, a parasitic mite that colonizes human skin and is also associated with rosacea. However, the relative contributions of D. folliculorum and B. oleronius to the pathology of rosacea have not yet been determined.

    Prodigiosin is a red pigment that is produced by bacteria from a number of genera: Serratia, Hahella, Streptomyces, Saccharopolyspora, Zooshikella, Vibrio, and others in the class Gammaproteobacteria. In isolation, the pigment exhibits antimicrobial activity against a wide range of Gram-positive and Gram-negative bacteria. It is also been demonstrated to possess antifungal and antiprotozoal activity as well as the ability to prevent biofouling by marine barnacles. While many potential medical and technological applications for prodigiosin and related pigments have been identified, the biological role of prodigiosin for the bacterial species producing the pigment has not been determined. Prodigiosin production did not impact the virulence of Serratia marcescens in artificial infections of the model organism silkworm, Bombyx mori.

    Multiple species of bacteria from the genus Bacillus have exhibited sensitivity to prodigiosin. More specifically, prodigiosin treatment of Bacillus subtilis during the exponential phase caused immediate bacterial death and a corresponding decrease in the optical density of the culture. In a series of follow-up experiments by Danevčič et al. the mechanism of death was further defined. Using an ONPG/β-galactosidase substrate internalization assay, the researchers demonstrated that prodigiosin treatment resulted in cytoplasmic membrane leakage. Furthermore, a modified comet assay revealed the release of nucleic acid diffusion from the cells, a hallmark of cellular lysis. Herein we build on the work of Danevčič et al. and demonstrate the bactericidal effect of prodigiosin on B. oleronius.

  • Objective

    We first became interested in exploring the prodigiosin sensitivity of B. oleronius after learning of the sensitivity of several Bacillus species to prodigiosin and related compounds. As a growing body of scientific evidence has implicated B. oleronius in the pathology of rosacea, we believed defining the sensitivity of B. oleronius to prodigiosin was scientifically warranted.

  • Results & Discussion

    Prodigiosin and Topical Antibiotic Minimum Inhibitory Concentrations

    In the microdilution assay, the average MIC of prodigiosin against B. oleronius was 0.75 (0.289) μg/mL and ranged between 0.5 μg/mL and 1 μg/mL in 4 independent experiments. This MIC is lower than the MICs that have been reported for other species in the genus Bacillus, which range between 5.2 μg/mL and 6.9 μg/mL in one study and 100 μg/mL in another study. As we utilized the same experimental methodology as Danevčič et al. for this experiment, our results are directly comparable.

    As a means of comparison, we also determined the MICs of common topical antibiotics against B. oleronius. The prodigiosin MIC was similar to the MICs of bacitracin, 0.5 (0) μg/mL and clindamycin, 1 (0) μg/mL, but it was greater than the MIC of neomycin, 32 (0) ng/mL.

    Impact of Prodigiosin During Bacillus oleronius Exponential Growth Phase

    Despite the apparent difference in prodigiosin sensitivity, prodigiosin exerts a similar bactericidal effect on B. oleronius as it does on B. subtilis when cells are treated during the exponential growth phase. We treated B. oleronius cultures with 4 concentrations of prodigiosin that bracket the 0.75 μg/mL MIC or an equivalent concentration of 0.05% (v/v) ethanol (Fig. 1). Bacterial growth in ethanol control remained identical to the untreated control throughout the 405 min growth curve. All of the prodigiosin treatments resulted in a reduction in culture density within 30 min of addition as measured by OD650. Both the 0.25 μg/mL and 0.5 μg/mL prodigiosin conditions maintained a positive growth trajectory following treatment, although both exhibited a marked reduction in growth rate compared to the ethanol control. The 1 μg/mL and 2 μg/mL prodigiosin conditions had even more dramatic effects on the culture density. The 1 μg/mL prodigiosin treatment resulted in the OD650 remaining unchanged for the duration of the experiment, indicating a complete inhibition of bacterial growth. The 2 μg/mL prodigiosin treatment resulted in a steady decline in culture density, similar to the 5.9 μg/mL prodigiosin treatment of exponential phase B. subtilis by Danevčič et al.. While we did not explore the nature of this decline in OD650, we hypothesize that the 2 μg/mL prodigiosin condition caused the lysis of B. oleronius as previously demonstrated for B. subtilis. Our observation builds on the body of scientific literature that demonstrates the potential medically relevant applications of prodigiosin.

  • Conclusions

    In summation, we demonstrate that the average MIC of prodigiosin against B. oleronius was 0.75 (0.289) μg/mL in a broth microdilution assay. As previously demonstrated for B. subtilis, prodigiosin exerts a bactericidal effect against B. oleronius when the compound is applied during the exponential growth phase.

  • Limitations

    Prodigiosin is produced by a number of bacterial genera. The compound used in our study was isolated from Gammaproteobacterium strain MS-02-063, while Danevčič et al. extracted prodigiosin from Vibrio ruber strain DSM 14379. As the prodigiosin from these distinct species of bacteria has the same chemical structure, the results of our experiments should be comparable. However, the difference in prodigiosin source should be considered as a potential source of variation between the experiments.

    Additionally, our experiments were conducted with a single strain of B. oleronius. In order to explore the potential for prodigiosin to be utilized in a clinical context for the treatment of rosacea, future experiments should include additional strains of B. oleronius that have been isolated from human skin.

  • Conjectures

    As the presence of B. oleronius is associated with rosacea, future studies could examine the effectiveness of topical prodigiosin application for treatment of the skin condition. If tested, prodigiosin should be explored in isolation and in conjunction with other rosacea treatments.

  • Methods

    Bacterial Strain and Media

    The bacterial strain used in this study was Bacillus oleronius strain ATCC 700005 (ATCC, Manassas, VA, USA). Bacteria were cultured in Muller Hinton II (MHII) broth at 37°C (Becton Dickson and Company, Sparks, MD, USA).

    Broth Microdilution Assay

    Minimum inhibitory concentrations (MIC) for bacitracin, CAS 1405-87-4 (Acros Organics, Fair Lawn, NJ, USA), clindamycin, CAS 58207-19-5 (Tokyo Chemical Industry CO., Tokyo, Japan), neomycin, CAS 1405-10-3 (Fisher BioReagents, Fair Lawn, NJ, USA), and prodigiosin, CAS 82-89-3 (AdipoGen, San Diego, CA, USA) were determined using the broth microdilution assay described by the Clinical and Laboratory Standards Institute. Briefly, a 1:2 dilution series of prodigiosin was prepared in a 96-well microtiter plate. Overnight cultures of B. oleronius were diluted in MHII broth and inoculated to a final concentration of 5×104 CFU/well. The total volume in each microtiter well was 100 μL. For the prodigiosin experiment, the concentration of ethanol was maintained at 0.8% (v/v) in all conditions. MICs were determined by visual inspection following 16–18 h of static incubation at 37°C. Using unaided eye observation, we determined the MIC to be the lowest concentration of a compound that completely inhibited bacterial growth. The MIC values reported here represent the average of 4 independent experiments for prodigiosin and clindamycin and the average of 5 independent experiments for bacitracin and neomycin. The MIC values are reported in the following format: average (SD).

    Growth Curve with Prodigiosin Addition

    An overnight culture of B. oleronius was diluted 1:100 into fresh MHII broth and divided into 7 mL cultures. The freshly diluted cultures were grown at 37°C with shaking at 200 rpm. Bacterial growth was monitored by measuring optical density at 650 nm (OD650) using a Spectronic 20D (Milton Roy, Dallas, TX, USA). For the first 180 min, OD650 was measured at 60 min intervals. After 195 min of growth, either prodigiosin, an equivalent volume of ethanol, or plain MHII broth, was aseptically added to the cultures. The tubes were then returned to the shaking incubator for 30 min prior to the next OD650 measurement. Subsequently, culture density at OD650 was measured at 30 min intervals for an additional 210 min. The concentration of ethanol was maintained at 0.05% (v/v) in prodigiosin and ethanol control conditions. The growth curves reported here represent the average of 3 independent experiments.

  • Ethics statement

    Not Applicable.

  • References
  • 1
    Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum

    Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum ipsum Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum ipsum

    Lorem ipsum Lorem ipsum Lorem ipsum
    2
    Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum

    Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum ipsum Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum ipsum

    Lorem ipsum Lorem ipsum Lorem ipsum
    3
    Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum

    Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum ipsum Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum ipsum

    Lorem ipsum Lorem ipsum Lorem ipsum
    4
    Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum

    Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum ipsum Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum ipsum

    Lorem ipsum Lorem ipsum Lorem ipsum
    5
    Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum

    Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum ipsum Lorem ipsum Lorem ipsum Lorem ipsum Lorem ipsum ipsum

    Lorem ipsum Lorem ipsum Lorem ipsum
    Matters11.5/20

    Sensitivity of Bacillus oleronius, a bacterium that is associated with rosacea, to prodigiosin

    Affiliation listing not available.
    Continuing the storyline of

  • Danevčič Tjaša, Borić Vezjak Maja, Tabor Maja,more_horiz, Stopar David
    Prodigiosin Induces Autolysins in Actively Grown Bacillus subtilis Cells
    Frontiers in Microbiology, 7/2016 DOI: 10.3389/fmicb.2016.00027chrome_reader_mode
  • Abstractlink

    Prodigiosin is a red bacterial pigment that exhibits antimicrobial activity against a wide range of microorganisms. Bacillus oleronius is a bacterium that is associated with rosacea, a long-term skin condition that affects the face and typically results in pimples, redness, and swelling of the skin. We explored the effect of prodigiosin on the growth of B. oleronius. Prodigiosin completely inhibited the growth of B. oleronius in a broth microdilution assay at 0.75 (0.289) μg/mL, lower than previously reported minimum inhibitory concentration values for other species of Bacillus. We also observed a rapid decline in the optical density of mid-log phase B. oleronius cultures immediately upon treatment with prodigiosin, suggesting that prodigiosin exerts bactericidal activity on actively dividing cells.

    Figurelink

    Figure 1. The effect of prodigiosin on the exponential phase growth of Bacillus oleronius.

    Optical densities (OD650) of freshly diluted 7 mL B. oleronius cultures at 37°C with shaking at 200 rpm were monitored for 405 min. Prodigiosin or the appropriate diluent control was added after 195 min of growth, during the exponential growth phase. The mean of 3 independent experiments is shown. Error bars represent SD.

    Introductionlink

    Rosacea is a facial skin disorder that causes a wide range of symptoms from persistent redness of the skin to eye irritation. It is a chronic inflammatory disease with a typical onset at age 30 or older[1][2]. Rosacea is estimated to affect 5.46% of the global adult population[3]. In the United States, an estimated 82% of rosacea cases remain untreated, resulting in long-term skin conditions that are sometimes characterized by cycles of remission and relapse[4].

    While the exact cause of rosacea is unknown, a growing body of literature suggests that the condition may be caused or exacerbated by the presence of a bacterium called Bacillus oleronius[5]. Compared to the general population, rosacea patients are more likely to have circulating antibodies against B. oleronius, suggesting previous exposure to and immune response against the bacterium[6][7][8]. Additionally, B. oleronius proteins have the ability to activate peripheral blood mononuclear cells and neutrophils, causing the release of pro-inflammatory cytokines[9][10]. More generally, some antibiotics of the tetracycline and macrolide groups are effective in the treatment of some types of rosacea, suggesting that a bacterial agent may be involved in the pathogenesis of the disease[11][12][13]. However, these antibiotics also have an anti-inflammatory response that likely alleviates rosacea symptoms[12][13]. The potential association between B. oleronius and rosacea is further complicated by the bacterium’s commensal relationship with Demodex folliculorum, a parasitic mite that colonizes human skin and is also associated with rosacea[9][14][15][16]. However, the relative contributions of D. folliculorum and B. oleronius to the pathology of rosacea have not yet been determined.

    Prodigiosin is a red pigment that is produced by bacteria from a number of genera: Serratia, Hahella, Streptomyces, Saccharopolyspora, Zooshikella, Vibrio, and others in the class Gammaproteobacteria[17][18]. In isolation, the pigment exhibits antimicrobial activity against a wide range of Gram-positive and Gram-negative bacteria[19][20][21][22]. It is also been demonstrated to possess antifungal and antiprotozoal activity[23][24] as well as the ability to prevent biofouling by marine barnacles[25]. While many potential medical and technological applications for prodigiosin and related pigments have been identified, the biological role of prodigiosin for the bacterial species producing the pigment has not been determined[26][27]. Prodigiosin production did not impact the virulence of Serratia marcescens in artificial infections of the model organism silkworm, Bombyx mori[28].

    Multiple species of bacteria from the genus Bacillus have exhibited sensitivity to prodigiosin[19][25][22]. More specifically, prodigiosin treatment of Bacillus subtilis during the exponential phase caused immediate bacterial death and a corresponding decrease in the optical density of the culture[22]. In a series of follow-up experiments by Danevčič et al. the mechanism of death was further defined. Using an ONPG/β-galactosidase substrate internalization assay, the researchers demonstrated that prodigiosin treatment resulted in cytoplasmic membrane leakage[22]. Furthermore, a modified comet assay revealed the release of nucleic acid diffusion from the cells, a hallmark of cellular lysis[22]. Herein we build on the work of Danevčič et al. and demonstrate the bactericidal effect of prodigiosin on B. oleronius.

    Objectivelink

    We first became interested in exploring the prodigiosin sensitivity of B. oleronius after learning of the sensitivity of several Bacillus species to prodigiosin and related compounds[19][29][25][22]. As a growing body of scientific evidence has implicated B. oleronius in the pathology of rosacea, we believed defining the sensitivity of B. oleronius to prodigiosin was scientifically warranted.

    Results & Discussionlink

    Prodigiosin and Topical Antibiotic Minimum Inhibitory Concentrations

    In the microdilution assay, the average MIC of prodigiosin against B. oleronius was 0.75 (0.289) μg/mL and ranged between 0.5 μg/mL and 1 μg/mL in 4 independent experiments. This MIC is lower than the MICs that have been reported for other species in the genus Bacillus, which range between 5.2 μg/mL and 6.9 μg/mL in one study[22] and 100 μg/mL in another study[25]. As we utilized the same experimental methodology as Danevčič et al. for this experiment, our results are directly comparable[30][22].

    As a means of comparison, we also determined the MICs of common topical antibiotics against B. oleronius. The prodigiosin MIC was similar to the MICs of bacitracin, 0.5 (0) μg/mL and clindamycin, 1 (0) μg/mL, but it was greater than the MIC of neomycin, 32 (0) ng/mL.

    Impact of Prodigiosin During Bacillus oleronius Exponential Growth Phase

    Despite the apparent difference in prodigiosin sensitivity, prodigiosin exerts a similar bactericidal effect on B. oleronius as it does on B. subtilis when cells are treated during the exponential growth phase[22]. We treated B. oleronius cultures with 4 concentrations of prodigiosin that bracket the 0.75 μg/mL MIC or an equivalent concentration of 0.05% (v/v) ethanol (Fig. 1). Bacterial growth in ethanol control remained identical to the untreated control throughout the 405 min growth curve. All of the prodigiosin treatments resulted in a reduction in culture density within 30 min of addition as measured by OD650. Both the 0.25 μg/mL and 0.5 μg/mL prodigiosin conditions maintained a positive growth trajectory following treatment, although both exhibited a marked reduction in growth rate compared to the ethanol control. The 1 μg/mL and 2 μg/mL prodigiosin conditions had even more dramatic effects on the culture density. The 1 μg/mL prodigiosin treatment resulted in the OD650 remaining unchanged for the duration of the experiment, indicating a complete inhibition of bacterial growth. The 2 μg/mL prodigiosin treatment resulted in a steady decline in culture density, similar to the 5.9 μg/mL prodigiosin treatment of exponential phase B. subtilis by Danevčič et al.. While we did not explore the nature of this decline in OD650, we hypothesize that the 2 μg/mL prodigiosin condition caused the lysis of B. oleronius as previously demonstrated for B. subtilis. Our observation builds on the body of scientific literature that demonstrates the potential medically relevant applications of prodigiosin.

    Conclusionslink

    In summation, we demonstrate that the average MIC of prodigiosin against B. oleronius was 0.75 (0.289) μg/mL in a broth microdilution assay. As previously demonstrated for B. subtilis[22], prodigiosin exerts a bactericidal effect against B. oleronius when the compound is applied during the exponential growth phase.

    Limitationslink

    Prodigiosin is produced by a number of bacterial genera. The compound used in our study was isolated from Gammaproteobacterium strain MS-02-063[31], while Danevčič et al. extracted prodigiosin from Vibrio ruber strain DSM 14379[22]. As the prodigiosin from these distinct species of bacteria has the same chemical structure, the results of our experiments should be comparable. However, the difference in prodigiosin source should be considered as a potential source of variation between the experiments.

    Additionally, our experiments were conducted with a single strain of B. oleronius. In order to explore the potential for prodigiosin to be utilized in a clinical context for the treatment of rosacea, future experiments should include additional strains of B. oleronius that have been isolated from human skin.

    Conjectureslink

    As the presence of B. oleronius is associated with rosacea, future studies could examine the effectiveness of topical prodigiosin application for treatment of the skin condition. If tested, prodigiosin should be explored in isolation and in conjunction with other rosacea treatments.

    Methodslink

    Bacterial Strain and Media

    The bacterial strain used in this study was Bacillus oleronius strain ATCC 700005 (ATCC, Manassas, VA, USA). Bacteria were cultured in Muller Hinton II (MHII) broth at 37°C (Becton Dickson and Company, Sparks, MD, USA).

    Broth Microdilution Assay

    Minimum inhibitory concentrations (MIC) for bacitracin, CAS 1405-87-4 (Acros Organics, Fair Lawn, NJ, USA), clindamycin, CAS 58207-19-5 (Tokyo Chemical Industry CO., Tokyo, Japan), neomycin, CAS 1405-10-3 (Fisher BioReagents, Fair Lawn, NJ, USA), and prodigiosin, CAS 82-89-3 (AdipoGen, San Diego, CA, USA) were determined using the broth microdilution assay described by the Clinical and Laboratory Standards Institute[30]. Briefly, a 1:2 dilution series of prodigiosin was prepared in a 96-well microtiter plate. Overnight cultures of B. oleronius were diluted in MHII broth and inoculated to a final concentration of 5×104 CFU/well. The total volume in each microtiter well was 100 μL. For the prodigiosin experiment, the concentration of ethanol was maintained at 0.8% (v/v) in all conditions. MICs were determined by visual inspection following 16–18 h of static incubation at 37°C. Using unaided eye observation, we determined the MIC to be the lowest concentration of a compound that completely inhibited bacterial growth. The MIC values reported here represent the average of 4 independent experiments for prodigiosin and clindamycin and the average of 5 independent experiments for bacitracin and neomycin. The MIC values are reported in the following format: average (SD).

    Growth Curve with Prodigiosin Addition

    An overnight culture of B. oleronius was diluted 1:100 into fresh MHII broth and divided into 7 mL cultures. The freshly diluted cultures were grown at 37°C with shaking at 200 rpm. Bacterial growth was monitored by measuring optical density at 650 nm (OD650) using a Spectronic 20D (Milton Roy, Dallas, TX, USA). For the first 180 min, OD650 was measured at 60 min intervals. After 195 min of growth, either prodigiosin, an equivalent volume of ethanol, or plain MHII broth, was aseptically added to the cultures. The tubes were then returned to the shaking incubator for 30 min prior to the next OD650 measurement. Subsequently, culture density at OD650 was measured at 30 min intervals for an additional 210 min. The concentration of ethanol was maintained at 0.05% (v/v) in prodigiosin and ethanol control conditions. The growth curves reported here represent the average of 3 independent experiments.

    Conflict of interestlink

    The authors declare no conflicts of interest.

    Ethics Statementlink

    Not Applicable.

    No fraudulence is committed in performing these experiments or during processing of the data. We understand that in the case of fraudulence, the study can be retracted by ScienceMatters.

    Referenceslink
    1. Christos C. Zouboulis, Andreas D. Katsambas, Albert M. Kligman
      Pathogenesis and Treatment of Acne and Rosacea
      Springer, Berlin, Heidelber, 2014, page 749 DOI: 10.1007/978-3-540-69375-8chrome_reader_mode
    2. Richard L. Gallo, Richard D. Granstein, Sewon Kang,more_horiz, Diane Thiboutot
      Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee
      Journal of the American Academy of Dermatology, 78/2018, pages 148-155 DOI: 10.1016/j.jaad.2017.08.037chrome_reader_mode
    3. L. Gether, L. K. Overgaard, A. Egeberg, J. P. Thyssen
      Incidence and prevalence of rosacea: a systematic review and meta‐analysis
      British Journal of Dermatology, 179/2018, pages 282-289 DOI: 10.1111/bjd.16481chrome_reader_mode
    4. Brooke Wehausen, Dane E. Hill, Steven R. Feldman
      Most people with psoriasis or rosacea are not being treated: a large population study
      Dermatology Online Journal, 22/2016 chrome_reader_mode
    5. Stanisław Jarmuda, Niamh O’reilly, Ryszard Żaba, Oliwia Jakubowicz, Andrzej Szkaradkiewicz, Kevin Kavanagh
      Potential role of Demodex mites and bacteria in the induction of rosacea
      Journal of Medical Microbiology, 61/2012, pages 1504-1510 DOI: 10.1099/jmm.0.048090-0chrome_reader_mode
    6. Jianjing Li, Niamh O'Reilly, Hosam Sheha,more_horiz, Scheffer C.G. Tseng
      Correlation between Ocular Demodex Infestation and Serum Immunoreactivity to Bacillus Proteins in Patients with Facial Rosacea
      Ophthalmology, 117/2010, pages 870-877.e1 DOI: 10.1016/j.ophtha.2009.09.057chrome_reader_mode
    7. N. O’reilly, N. Menezes, K. Kavanagh
      Positive correlation between serum immunoreactivity to Demodex‐associated Bacillus proteins and erythematotelangiectatic rosacea
      British Journal of Dermatology, 167/2012, pages 1032-1036 DOI: 10.1111/j.1365-2133.2012.11114.xchrome_reader_mode
    8. Stanisław Jarmuda, Fred McMahon, Ryszard Żaba, Niamh O'Reilly, Oliwia Jakubowicz, Ashling Holland, Andrzej Szkaradkiewicz, Kevin Kavanagh
      Correlation between serum reactivity to Demodex-associated Bacillus oleronius proteins, and altered sebum levels and Demodex populations in erythematotelangiectatic rosacea patients
      Journal of Medical Microbiology, 63/2014, pages 258-262 DOI: 10.1099/jmm.0.065136-0chrome_reader_mode
    9. N. Lacey, S. Delaney, K. Kavanagh, F. C. Powell
      Mite‐related bacterial antigens stimulate inflammatory cells in rosacea
      British Journal of Dermatology, 157/2007, pages 474-481 DOI: 10.1111/j.1365-2133.2007.08028.xchrome_reader_mode
    10. N. O’reilly, D. Bergin, E. P. Reeves, N. G. McElvaney, K. Kavanagh
      Demodex‐associated bacterial proteins induce neutrophil activation
      British Journal of Dermatology, 166/2012, pages 753-760 DOI: 10.1111/j.1365-2133.2011.10746.xchrome_reader_mode
    11. Ö Bakar, Z Demircay, E Toker, S Çakır
      Ocular signs, symptoms and tear function tests of papulopustular rosacea patients receiving azithromycin
      Journal of the European Academy of Dermatology and Venereology, 23/2009, pages 544-549 DOI: 10.1111/j.1468-3083.2009.03132.xchrome_reader_mode
    12. Martin Steinhoff, Marc Vocanson, Johannes J Voegel, Feriel Hacini-Rachinel, Gregor Schäfer
      Topical Ivermectin 10 mg/g and Oral Doxycycline 40 mg Modified-Release: Current Evidence on the Complementary Use of Anti-Inflammatory Rosacea Treatments
      Advances in Therapy, 33/2016, pages 1481-1501 DOI: 10.1007/s12325-016-0380-zchrome_reader_mode
    13. Alexis Lara Rivero, Margot Whitfeld
      An update on the treatment of rosacea
      Australian Prescriber, 41/2018, pages 20-24 DOI: 10.18773/austprescr.2018.004chrome_reader_mode
    14. A. Szkaradkiewicz, I. Chudzicka-Strugała, T.M. Karpiński,more_horiz, R. Zaba
      Bacillus oleronius and Demodex mite infestation in patients with chronic blepharitis
      Clinical Microbiology and Infection, 18/2012, pages 1020-1025 DOI: 10.1111/j.1469-0691.2011.03704.xchrome_reader_mode
    15. Leah A Cardwell, Hossein Alinia, Sara Moradi Tuchayi, Steven R Feldman
      New developments in the treatment of rosacea – role of once-daily ivermectin cream
      Clinical, Cosmetic and Investigational Dermatology, 9/2016, pages 71-77 DOI: 10.2147/ccid.s98091chrome_reader_mode
    16. Ellen M. Moran, Ruth Foley, Frank C. Powell
      Demodex and rosacea revisited
      Clinics in Dermatology, 35/2017, pages 195-200 DOI: 10.1016/j.clindermatol.2016.10.014chrome_reader_mode
    17. Takuji Nakashima, Tadashi Tamura, Maki Kurachi, Kenichi Yamaguchi, Tatsuya Oda
      Apoptosis-Mediated Cytotoxicity of Prodigiosin-Like Red Pigment Produced by γ-Proteobacterium and Its Multiple Bioactivities
      Biological and Pharmaceutical Bulletin, 28/2005, pages 2289-2295 DOI: 10.1248/bpb.28.2289chrome_reader_mode
    18. Nada Stankovic, Lidija Senerovic, Tatjana Ilic-Tomic, Branka Vasiljevic, Jasmina Nikodinovic-Runic
      Properties and applications of undecylprodigiosin and other bacterial prodigiosins
      Applied Microbiology and Biotechnology, 98/2014, pages 3841-3858 DOI: 10.1007/s00253-014-5590-1chrome_reader_mode
    19. Jong Suk Lee, Yong-Sook Kim, Sooyeon Park, Jihoon Kim, So-Jung Kang, Mi-Hwa Lee, Sangryeol Ryu, Jong Myoung Choi, Tae-Kwang Oh, Jung-Hoon Yoon
      Exceptional Production of both Prodigiosin and Cycloprodigiosin as Major Metabolic Constituents by a Novel Marine Bacterium, Zooshikella rubidus S1-1
      Applied and Environmental Microbiology, 77/2011, pages 4967-4973 DOI: 10.1128/aem.01986-10chrome_reader_mode
    20. Antony V. Samrot, Chandana K, Senthilkumar P, Narendra Kumar G
      Optimization of prodigiosin production by Serratia marcescens SU-10 and evaluation of its bioactivity
      International Research Journal of Biotechnology, 2/2011, pages 128-133 chrome_reader_mode
    21. J. C. Lapenda, P. A. Silva, M. C. Vicalvi, K. X. F. R. Sena, S. C. Nascimento
      Antimicrobial activity of prodigiosin isolated from Serratia marcescens UFPEDA 398
      World Journal of Microbiology and Biotechnology, 31/2014, pages 399-406 DOI: 10.1007/s11274-014-1793-ychrome_reader_mode
    22. Tjaša Danevčič, Maja Borić Vezjak, Maja Tabor, Maša Zorec, David Stopar
      Prodigiosin Induces Autolysins in Actively Grown Bacillus subtilis Cells
      Frontiers in Microbiology, 7/2016, page 27 DOI: 10.3389/fmicb.2016.00027chrome_reader_mode
    23. Nobutaka Someya, Masami Nakajima, Kazuyuki Hirayae, Tadaaki Hibi, Katsumi Akutsu
      Synergistic Antifungal Activity of Chitinolytic Enzymes and Prodigiosin Produced by Biocontrol Bacterium, Serratia marcescens Strain B2 against Gray Mold Pathogen, Botrytis cinerea
      Journal of General Plant Pathology, 67/2001, pages 312-317 DOI: 10.1007/pl00013038chrome_reader_mode
    24. Carlos Genes, Eduard Baquero, Fernando Echeverri, Juan D Maya, Omar Triana
      Mitochondrial dysfunction in Trypanosoma cruzi: the role of Serratia marcescens prodigiosin in the alternative treatment of Chagas disease
      Parasites & Vectors, 4/2011, page 66 DOI: 10.1186/1756-3305-4-66chrome_reader_mode
    25. K. Ananda Priya, S. Satheesh, B. Ashokkumar, P. Varalakshmi, G. Selvakumar, N. Sivakumar
      Antifouling Activity of Prodigiosin from Estuarine Isolate of Serratia marcescens CMST 07
      Microbiological Research In Agroecosystem Management, 2013, pages 11-21 DOI: 10.1007/978-81-322-1087-0_2chrome_reader_mode
    26. Neil R. Williamson, Peter C. Fineran, Finian J. Leeper, George P. C. Salmond
      The biosynthesis and regulation of bacterial prodiginines
      Nature Reviews Microbiology, 4/2006, pages 887-899 DOI: 10.1038/nrmicro1531chrome_reader_mode
    27. N. Darshan, H. K. Manonmani
      Prodigiosin and its potential applications
      Journal of Food Science and Technology, 52/2015, pages 5393-5407 DOI: 10.1007/s13197-015-1740-4chrome_reader_mode
    28. Wei Zhou, Jinghua Li, Jie Chen,more_horiz, Yongji Wan
      The red pigment prodigiosin is not an essential virulence factor in entomopathogenic Serratia marcescens
      Journal of Invertebrate Pathology, 136/2016, pages 92-94 DOI: 10.1016/j.jip.2016.03.011chrome_reader_mode
    29. Nada Stankovic, Vanja Radulovic, Milos Petkovic, Ivan Vuckovic, Milka Jadranin, Branka Vasiljevic, Jasmina Nikodinovic-Runic
      Streptomyces sp. JS520 produces exceptionally high quantities of undecylprodigiosin with antibacterial, antioxidative, and UV-protective properties
      Applied Microbiology and Biotechnology, 96/2012, pages 1217-1231 DOI: 10.1007/s00253-012-4237-3chrome_reader_mode
    30. Clinical, Laboratory Standards Institute
      Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Ninth Edition
      M07–A9, 32/2012 chrome_reader_mode
    31. Takuji Nakashima, Maki Kurachi, Yoko Kato, Kenichi Yamaguchi, Tatsuya Oda
      Characterization of Bacterium Isolated from the Sediment at Coastal Area of Omura Bay in Japan and Several Biological Activities of Pigment Produced by This Isolate
      Microbiology and Immunology, 49/2005, pages 407-415 DOI: 10.1111/j.1348-0421.2005.tb03744.xchrome_reader_mode
    Commentslink

    Create a Matters account to leave a comment.